Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.
The relationship between the plasma concentration of oxprenolol and its haemodynamic effects during physical exercise was studied in 6 healthy volunteers, in whom BP and heart rate (HR) were continuously monitored by non-invasive techniques (Fin-A-Press-Tonometer) during repeated three-minute exercise periods for 8 h after treatment. Using the fitted pharmacokinetic curve, the drug effect was related to its plasma concentration using the Emax model. The mean EC50 for the relationship between drug concentration and heart rate during exercise (HRex) was 73.1 ng/ml, and for systolic blood pressure during exercise (SBPex) it was 112.7 ng/ml. Emax was 29.0% for HRex, and 33.2% for SBPex. There were no consistent differences between the parameters for the effects on HRex and SPBex. Thus, using a new, non-invasive technique for continuous measurement of blood pressure, the effect of a beta-adrenoceptor blocking drug on SBPex was described with similar accuracy as its effect on HRex.
Koopmans
R
R
Department of Medicine, University of Amsterdam, The Netherlands.
Oosterhuis
B
B
Karemaker
J M
JM
Wemer
J
J
van Boxtel
C J
CJ
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D002851:Chromatography, High Pressure Liquid; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D010096:Oxprenolol / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*
D010096:Oxprenolol